Dong-A Pharmaceutical동아제약
000640 · KOSPI · ₩000640 · 동아제약
₩86,900▲ ₩600 (0.70%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩1.4T | ₩1.3T | ₩1.1T | ₩1T | ₩882B |
| Cost of sales | ₩973B | ₩925B | ₩1.1T | ₩977B | ₩820B |
| Gross profit | ₩457B | ₩408B | ₩77B | ₩38B | ₩62B |
| Operating income | ₩98B | ₩82B | ₩77B | ₩38B | ₩62B |
| Net income | ₩91B | ₩58B | ₩56B | ₩7.8B | ₩61B |
| Net income to shareholders | ₩91B | ₩58B | ₩58B | ₩11B | ₩60B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩2.1T | ₩2T | ₩2T | ₩1.7T | ₩1.7T |
| Current assets | ₩504B | ₩449B | ₩414B | ₩338B | ₩359B |
| Cash and equivalents | ₩123B | ₩117B | ₩120B | ₩95B | ₩100B |
| Total liabilities | ₩928B | ₩967B | ₩930B | ₩733B | ₩706B |
| Current liabilities | ₩674B | ₩703B | ₩629B | ₩566B | ₩467B |
| Borrowings | ₩558B | ₩626B | ₩588B | ₩500B | ₩483B |
| Total equity | ₩1.2T | ₩1.1T | ₩1T | ₩999B | ₩985B |
| Shareholders' equity | ₩1.1T | ₩1T | ₩1T | ₩982B | ₩965B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩227B | ₩83B | ₩159B | ₩76B | ₩131B |
| Capital spending | ₩49B | ₩50B | ₩150B | ₩57B | ₩70B |
| Free cash flow | ₩178B | ₩33B | ₩8.6B | ₩19B | ₩61B |
| Dividends paid | ₩11B | ₩12B | ₩13B | ₩9.4B | ₩9.2B |
Consolidated where available. Amounts in won.
Also known as: Dong-A Pharmaceutical / 동아제약 / 000640 / KRX:000640
Source: KRX statistical information